Article, News
Prescient (ASX: PTX) signs off FY22 with solid progress in clinical pipeline
Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) is working towards expanding its next-generation cell immunotherapy program. At the same time, Prescient is advancing major clinical programs, PTX-100 and…
Article, News
Prescient signs cell manufacturing deal ahead of OmniCAR trials
An Australian company developing personalised therapies for cancer has joined forces with a specialist cell therapy manufacturer to bolster its capabilities in the lead-up to…
News
Prescient secures OmniCAR cell lines for upcoming clinical trials
Prescient has entered a deal with the manufacturing arm of the world-renowned QIMR Berghofer Medical Research Institute in Brisbane to advance clinical trials of its…
Article, News
Prescient Therapeutics (ASX:PTX) locks in OmniCAR cell manufacturing contract for clinical trials
Prescient Therapeutics (PTX) has signed a manufacturing services agreement with Q-Gen Cell Therapeutics to produce its OmniCAR cell lines for its upcoming clinical trials.
News
Prescient Therapeutics sures supply of cell therapeutic in the hopes of commencing clinical trials
During the second World War, scientists noted that soldiers exposed to nitrogen mustard gas developed interesting hematologic pathology with significantly reduced white blood cell counts….
News
Prescient Therapeutics enters into OmniCAR cell production agreement with Q-Gen Cell
Q-Gen Cell will produce and deliver the OmniCAR cell lines from its Brisbane facility to be used for Prescient’s upcoming clinical trials.
News
Prescient Therapeutics signs deal with Q-Gen to enable OmniCAR clinical trials
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has entered a services agreement with specialist cell therapy manufacturer Q-Gen Cell Therapeutics for the manufacture of its OmniCAR cell…
News
Prescient Therapeutics (ASX: PTX) – Webinar Presentation
Steven Yatomi-Clarke – CEO & MD – Prescient Therapeutics is focused on developing novel, personalised therapies for a range of cancers.
News
The companies aiming to beat cancer serve up the highlights in the June quarter
Precedence Research suggests the global cancer therapeutics market size is predicted to surpass US$365.99 billion by 2030 and expand growth at a CAGR of 9.1%…